Welcome to our dedicated page for Ramm Pharma news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on Ramm Pharma stock.
RAMM Pharma Corp. (RAMMF) generates news that spans pharmaceutical cannabis, hemp-based products, veterinary CBD medicines and international expansion. Company releases emphasize its activities in cannabinoid pharmacology, registered plant-derived cannabinoid pharmaceuticals in Uruguay and several Latin American countries, and vertically integrated hemp and cannabis operations in Europe through subsidiaries such as Canapar Corp. and HemPoland.
Investors following RAMM-related news can expect updates on regulatory milestones, product registrations and approvals, particularly for cannabinoid pharmaceuticals and veterinary formulations like NettaVet 10% CBD Formulation. The company has highlighted approvals from Uruguayan authorities, progress at its GMP-certified formulation facility in Montevideo, and developments in European regulatory frameworks for CBD that affect its operations.
Corporate news has also covered acquisitions and integration of European businesses, including the purchase of HemPoland and the full acquisition of Canapar, as well as strategic initiatives to build a vertically integrated cannabis and hemp platform. More recent disclosures describe a proposed investment transaction with The Global South S.A.S., including details of the contemplated equity stake and call option, the need for financing, and the requirement for minority shareholder and regulatory approvals.
This news page aggregates such announcements, allowing readers to review RAMM s historical and ongoing disclosures about its pharmaceutical, veterinary, hemp and cannabis activities, its European and Latin American footprint, and its corporate transactions. Users interested in RAMM Pharma s evolving business model and regulatory environment can consult this feed for company-issued updates.
RAMM Pharma (CSE: RAMM / OTC: RAMMF) announced minority shareholders approved a proposed investment in The Global South S.A.S. at a Special Meeting on November 12, 2025. The Company will invest US$5.0 million for a 10% equity stake based on a post-investment valuation of US$50,000,000. RAMM will also receive a five-year call option to buy an additional 15% (bringing total ownership to 25%) at a future post-money valuation of US$400,000,000. The Company currently lacks the funds to close and is evaluating financing options; completion remains subject to definitive agreements and regulatory approvals.
RAMM Pharma (CSE:RAMMF) disclosed supplemental details for its proposed transaction with The Global South S.A.S ahead of the Special Meeting on November 12, 2025. RAMM proposes a US$5.0M investment for 10% of Global South (post-money valuation US$50M) and a five-year call option to increase ownership to 25% at a future post-money valuation of US$400M. The transaction is related-party (Global South owned by CEO Jackie Peter Burnett); Burnett and another officer will be excluded from voting, representing 22.57% ownership. RAMM currently lacks funds to close and expects to complete the transaction within nine months, subject to approvals and definitive documentation.
RAMM Pharma (CSE: RAMMF) notified shareholders on Oct 22, 2025 that Canada Post strike disruptions may delay delivery of proxy and meeting materials for the Special Meeting of Shareholders on Nov 12, 2025 at 2:30 p.m. Toronto time.
The Meeting Materials are available electronically on SEDAR+ and via Odyssey Trust at https://odysseytrust.com/client/ramm-pharma-corp-spc/. While materials were mailed, delivery before the meeting is not assured due to partial mail service and potential delays.
Registered shareholders can request a control number or voting help via Odyssey Trust’s chat or by calling 1-888-290-1175 (North America toll-free) or 1-587-885-0960 (outside North America). Beneficial shareholders should contact their brokerage or intermediary to request a proxy.
RAMM Pharma Corp. has updated its shareholders on ongoing litigation involving Sergio Martines and Naturale Science Inc. The trial occurred between April 29, 2024, and May 16, 2024, with the judge reserving the decision. Martines and Naturale Science Inc. are demanding approximately C$3 million from RAMM for breach of contract, specific performance, and out-of-pocket expenses. In response, RAMM has filed a counterclaim seeking C$14 million in damages for alleged fraudulent misrepresentation related to its acquisition of Canapar in June 2021. RAMM has accrued C$300,000 in its financial statements for possible liabilities, which may be adjusted in future reports.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
